Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Denali Therapeutics Inc. (DNLI) PT Lowered to $22 at Stifel
May 8, 2024 6:17 AM EDTStifel analyst Paul Mattels lowered the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $22.00 (from $26.00) while maintaining a Hold rating.
The analyst comments "Most importantly, DNLI is noting now that CDER "may be open to discussing an accelerated path" for... More
